Clinical utility of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing severe neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI plus bevacizumab: a single-center retrospective study.
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Bevacizumab
/ administration & dosage
Colorectal Neoplasms
/ drug therapy
Female
Fluorouracil
/ administration & dosage
Follow-Up Studies
Granulocyte Colony-Stimulating Factor
/ administration & dosage
Humans
Irinotecan
/ administration & dosage
Leucovorin
/ administration & dosage
Liver Neoplasms
/ drug therapy
Lung Neoplasms
/ drug therapy
Lymphatic Metastasis
Male
Middle Aged
Neutropenia
/ chemically induced
Oxaliplatin
/ administration & dosage
Peritoneal Neoplasms
/ drug therapy
Polyethylene Glycols
/ chemistry
Prognosis
Retrospective Studies
Survival Rate
FOLFOXIRI plus bevacizumab
Neutropenia
Polyethylene glycol conjugated granulocyte colony-stimulating factor
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
28 Apr 2020
28 Apr 2020
Historique:
received:
03
09
2019
accepted:
14
04
2020
entrez:
30
4
2020
pubmed:
30
4
2020
medline:
3
2
2021
Statut:
epublish
Résumé
This study aimed to evaluate the efficacy and the safety of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing neutropenia in metastatic colorectal cancer (mCRC) patients that received fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab (Bev) in clinical practice. We retrospectively analyzed mCRC patients who received FOLFOXIRI plus Bev between December 2015 and December 2017. We evaluated the efficacy of PEG-G-CSF as preventing or treating grade 3 or 4 neutropenia, the overall response rate (ORR) according to the Response Evaluation Criteria in Solid Tumors version 1.1, progression-free survival (PFS), overall survival (OS), and adverse events of FOLFOXIRI plus Bev based on the Common Terminology Criteria for Adverse Events version 4.0. A total of 26 patients (median age 53.5 years) were included. The ORR rate was 65.3%, the median PFS was 9.6 months (7.2-16.9), and the median OS was 24.2 months (13.6-NA). Grade 3 or 4 neutropenia occurred in 53.8% of the patients, and febrile neutropenia occurred in 7.7%. PEG-G-CSF was given to 77.0% of the patients, including prophylactically (n = 9) and after the development of grade 3 or 4 neutropenia (n = 11). No patients experienced grade 3 or 4 neutropenia after the administration of PEG-G-CSF. In seven of the nine patients who received PEG-G-CSF prophylactically (77.8%), no dose adjustment was required. PEG-G-CSF is useful in preventing severe neutropenia in mCRC patients treated with FOLFOXIRI plus Bev.
Sections du résumé
BACKGROUND
BACKGROUND
This study aimed to evaluate the efficacy and the safety of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing neutropenia in metastatic colorectal cancer (mCRC) patients that received fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab (Bev) in clinical practice.
METHODS
METHODS
We retrospectively analyzed mCRC patients who received FOLFOXIRI plus Bev between December 2015 and December 2017. We evaluated the efficacy of PEG-G-CSF as preventing or treating grade 3 or 4 neutropenia, the overall response rate (ORR) according to the Response Evaluation Criteria in Solid Tumors version 1.1, progression-free survival (PFS), overall survival (OS), and adverse events of FOLFOXIRI plus Bev based on the Common Terminology Criteria for Adverse Events version 4.0.
RESULTS
RESULTS
A total of 26 patients (median age 53.5 years) were included. The ORR rate was 65.3%, the median PFS was 9.6 months (7.2-16.9), and the median OS was 24.2 months (13.6-NA). Grade 3 or 4 neutropenia occurred in 53.8% of the patients, and febrile neutropenia occurred in 7.7%. PEG-G-CSF was given to 77.0% of the patients, including prophylactically (n = 9) and after the development of grade 3 or 4 neutropenia (n = 11). No patients experienced grade 3 or 4 neutropenia after the administration of PEG-G-CSF. In seven of the nine patients who received PEG-G-CSF prophylactically (77.8%), no dose adjustment was required.
CONCLUSIONS
CONCLUSIONS
PEG-G-CSF is useful in preventing severe neutropenia in mCRC patients treated with FOLFOXIRI plus Bev.
Identifiants
pubmed: 32345249
doi: 10.1186/s12885-020-06864-8
pii: 10.1186/s12885-020-06864-8
pmc: PMC7189469
doi:
Substances chimiques
Oxaliplatin
04ZR38536J
Granulocyte Colony-Stimulating Factor
143011-72-7
Bevacizumab
2S9ZZM9Q9V
Polyethylene Glycols
3WJQ0SDW1A
Irinotecan
7673326042
Leucovorin
Q573I9DVLP
Fluorouracil
U3P01618RT
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
358Références
Med Oncol. 2015 May;32(5):147
pubmed: 25820754
Clin Pharmacol Ther. 2004 Jun;75(6):501-15
pubmed: 15179405
J Clin Oncol. 2006 Jul 1;24(19):3187-205
pubmed: 16682719
Ann Oncol. 2003 Jan;14(1):29-35
pubmed: 12488289
BMC Cancer. 2008 Jul 10;8:195
pubmed: 18616811
Ann Oncol. 2016 May;27(5):843-9
pubmed: 26861604
Br J Haematol. 2016 Aug;174(4):563-70
pubmed: 27072050
J Clin Oncol. 2005 Feb 20;23(6):1178-84
pubmed: 15718314
Breast Cancer Res Treat. 2018 Apr;168(2):389-399
pubmed: 29230663
Clin Colorectal Cancer. 2010 Apr;9(2):95-101
pubmed: 20378503
Intern Med. 2019 Jul 15;58(14):1993-2002
pubmed: 30996164
Med Oncol. 2015 Jun;32(6):623
pubmed: 25966791
Ann Oncol. 2015 Sep;26(9):1948-1953
pubmed: 26122726
Br J Haematol. 2015 Jun;169(6):787-94
pubmed: 25819007
Cochrane Database Syst Rev. 2012 Oct 17;10:CD007913
pubmed: 23076939
Clin Cancer Res. 2009 Dec 1;15(23):7361-7
pubmed: 19920107
Ann Oncol. 2008 Feb;19(2):292-8
pubmed: 17846019
Pharmacogenet Genomics. 2005 May;15(5):295-301
pubmed: 15864130
Support Care Cancer. 2015 Apr;23(4):1137-43
pubmed: 25576433
Crit Rev Oncol Hematol. 2017 Oct;118:54-62
pubmed: 28917269
Anticancer Drugs. 2013 Jul;24(6):641-7
pubmed: 23571496
J Clin Oncol. 2007 May 1;25(13):1670-6
pubmed: 17470860
J Clin Oncol. 2004 Apr 1;22(7):1209-14
pubmed: 15051767
Ann Oncol. 2018 Jan 1;29(1):44-70
pubmed: 29155929
J Clin Oncol. 2003 Feb 1;21(3):514-9
pubmed: 12560443
J Clin Oncol. 2000 Jul;18(13):2522-8
pubmed: 10893282
Onco Targets Ther. 2016 Aug 04;9:4833-42
pubmed: 27536147
Oncologist. 2007 Dec;12(12):1416-24
pubmed: 18165618
Crit Rev Oncol Hematol. 2007 Oct;64(1):64-72
pubmed: 17317205
Clin Colorectal Cancer. 2017 Jun;16(2):103-114.e3
pubmed: 28038865
Crit Rev Oncol Hematol. 2010 Oct;76(1):61-70
pubmed: 19729318
Clin Colorectal Cancer. 2018 Jun;17(2):147-155
pubmed: 29530335
Support Care Cancer. 2016 Apr;24(4):1709-17
pubmed: 26423618
Cochrane Database Syst Rev. 2008 Oct 08;(4):CD003189
pubmed: 18843642
Future Oncol. 2016 Jun;12(11):1359-67
pubmed: 27020170
J Clin Oncol. 2006 May 20;24(15):2237-44
pubmed: 16636344
Ann Oncol. 2002 Jun;13(6):903-9
pubmed: 12123336
Leuk Lymphoma. 2003 Sep;44(9):1503-8
pubmed: 14565651
Lancet Oncol. 2010 Sep;11(9):845-52
pubmed: 20702138
Int J Clin Oncol. 2018 Feb;23(1):1-34
pubmed: 28349281
N Engl J Med. 2014 Oct 23;371(17):1609-18
pubmed: 25337750
Neoplasia. 2018 Dec;20(12):1219-1226
pubmed: 30412858
J Clin Oncol. 2002 Feb 1;20(3):727-31
pubmed: 11821454